The University of Texas MD Anderson Cancer Center Elekta MR Linac at ACB Vault 8 - 130724/BD Introduction to MD Anderson MD Anderson is known throughout the world for high-quality cancer care, research, academic programs and prevention services. Since its establishment in 1941, MD Anderson has made major contributions to improve the outlook for cancer patients everywhere. MD Anderson was one of the first three federally designated comprehensive cancer centers by the National Cancer Act of 1971. A survey of health professionals has routinely ranked MD Anderson as one of the two premier cancer centers in the nation for the past eight years. Over 55,000 persons annually seek care at MD Anderson. The team approach to cancer care, pioneered at MD Anderson, has been strengthened by consolidating specialty clinics into multi-disciplinary care centers that allow patients to receive more ambulatory care and treatment in a single location. MD Anderson offers one of the largest bone marrow and stem cell transplantation programs, as well as clinical trials to improve existing therapies. Teams of clinical specialists collaborate with scientists on problems of common interest and test theories that shorten the application of better treatment methods. Translational research studies are responsible for the promising field of chemoprevention, which uses synthetic vitamins to reverse pre-malignant lesions and halt the recurrence of some cancers, and for innovative gene therapy strategies being evaluated for several forms ofcancer. With faculty and staff working in more than 30 buildings in the greater Houston area and in central Texas, MD Anderson is the largest freestanding cancer center in the world. The physical plant covers more than 11 million square feet, featuring the latest equipment and facilities to support growing needs in outpatient and inpatient care, research, prevention and education. It includes inpatient hospital facilities with 571 beds. Construction projects include the addition of 12 floors that can accommodate more than 300 new inpatient beds in Alkek Hospital on the North Campus; two new research buildings on the South Campus that will house the Center for Advanced Biomedical Imaging Research and Center for Targeted Therapy as part of the McCombs Institute; and MD Anderson's first facility on its Mid Campus, a 25-story building to support current office space and future growth needs. In addition to its main campus in the Texas Medical Center and two research campuses in Bastrop County, Texas, MD Anderson has developed a number of local, national and international affiliations RFx Overview PRE-PROPOSAL CONFERENCE" October 9, 2014, 1:00 PM Local Time Mays Clinic (ACB) 1220 Holcombe Blvd. Room ACB 1.2345 Houston, Texas 77030 Owner seeks Construction Manager at Risk services for Project Number 130724 – Elekta MR Linac at Vault 8, which is generally described in the Project Description. Respondents to this RFP will be expected to interface with and provide support to the Owner and the Owner’s Project Architect. The University of Texas MD Anderson Cancer Center has joined a research group which will work to advance the development of image guided delivery of radiation therapy. This new technology will merge the precision of magnetic resonance imaging with the delivery of radiation therapy through the use of modern linear accelerators. The new machine, consisting of a Philips magnet combined with an Elekta digital accelerator will be situated in an existing linear accelerator vault in MD Anderson’s Mays Clinic. The existing vault is a shell space, with no linear accelerators having been installed in the space since construction of the building was completed. This project will prepare that shell space to receive this new technology. Questions related to this RFP must be sent via the information request form. All questions must be received no later than October 13, 2014 4:00 PM. Questions received after this time will not be accepted. Questions will not be answered via telephone. All answers to any questions or inquiries will be posted on the webpage for all Suppliers to access. It is the intent of MD Anderson to respond to all questions and concerns; however, MD Anderson shall reserve the right to decline to respond to any question or concern. It is important to note that the supplier or suppliers selected to develop MD Anderson's RFP are not automatically qualified to engage with the Institution for purposes of implementing the recommended strategy or solutions. The engagement of contracted services for implementation can, at MD Anderson's discretion, be solicited via a second and separate Request for Proposal. Standard Riders and Agreements AA RFP.pdf AAA 00 25 00 A_Harris.pdf AAA 00 25 00 B.pdf AAA 01 31 00.pdf AAA 01 32 00.pdf AAA 01 35 16.pdf AAA 01 35 25.pdf AAA 01 45 00.pdf AAA 01 57 23.pdf AAA 01 57 25.pdf AAA 01 77 00.pdf AAA 01 91 00.pdf AAA Addendum 1.pdf AAAA ADDENDUM 2 RFI QUESTIONS AND ANSWERS (3).pdf AAAA Addendum 2.pdf AAAAA 014 104 E1 REV P2.pdf AAAAA 014 104 E2 REV P2.pdf AAAAA 014 104 E3 REV P2.pdf AAAAA 014 104 E4 REV P2.pdf AAAAA 014 104 E5 REV P2.pdf AAAAA 014 104 M1 REV P2.pdf AAAAA 4240 07 B.pdf AAAAA 4240 Feasibility Detailed-08 B.pdf AAAAA Addendum 3.pdf AAAAA Floor Plan Drawing 1503509-DW-07_DRAFT.pdf AAAAA Plenum Drawing 1512876-DW-01_dft.pdf BB Final Draft Agreement.pdf CC Rider 1 to the Agreement.pdf DD RFI.pdf EE Rider 104 HUB Plan.pdf FF Rider 105 Affirmations and Warranties.pdf GG Rider 106 Premises Rules.pdf HH Rider 107 Travel Policy.pdf II Rider 117 Institutional Policies.pdf JJ Final Linac Feasibility Report.pdf KK 2013 UGC.pdf LL Attachment A Exhibit B 00 25 00 Owner's Special Conditions.pdf ***Interested suppliers should also note that Subcontracting Opportunities are probable in connection with this solicitation. Please review the HUB Subcontracting Tip Sheet ***RFx refers to RFP, RFQ, RFI, ITB, etc. Return to Supply Chain Management List of Current Bids.

Bid Protests Not Available